Cure My Disease

Don't miss your cure!

 Log in / Sign up

First patients receive experimental drug for aggressive, returning blood cancers

NCT ID NCT05512390

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This is the first study in people to test a new drug called ABBV-319 for several types of blood cancer that have come back or stopped responding to other treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it might help shrink tumors. About 154 adults with specific B-cell cancers will receive the drug by IV infusion in 21-day cycles.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Allina Health System /ID# 251782

    RECRUITING

    Minneapolis, Minnesota, 55407-1321, United States

  • Asan Medical Center /ID# 263220

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 05505, South Korea

  • Baylor Sammons Cancer Center /ID# 247715

    RECRUITING

    Dallas, Texas, 75246, United States

  • Concord Repatriation General Hospital /ID# 249240

    RECRUITING

    Concord, New South Wales, 2139, Australia

  • Cross Cancer Institute /ID# 246717

    COMPLETED

    Edmonton, Alberta, T6G 1Z2, Canada

  • Hadassah Medical Center-Hebrew University /ID# 254885

    RECRUITING

    Jerusalem, 91120, Israel

  • Hospital Universitario Fundacion Jimenez Diaz /ID# 265198

    RECRUITING

    Madrid, 28040, Spain

    Contact Phone: •••-•••-••••

  • Hospital Universitario Marques de Valdecilla /ID# 262826

    RECRUITING

    Santander, Cantabria, 39008, Spain

  • Memorial Sloan Kettering Cancer Center-Koch Center /ID# 249246

    RECRUITING

    New York, New York, 10065-6007, United States

  • Novant Health Presbyterian Medical Center /ID# 246719

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • One Clinical Research Pty Ltd /ID# 248392

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Samsung Medical Center /ID# 263294

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Hospital /ID# 263945

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • St Vincent's Hospital Melbourne /ID# 247624

    RECRUITING

    Fitzroy Melbourne, Victoria, 3065, Australia

  • Sylvester Comprehensive Cancer Center - University of Miami /ID# 247232

    COMPLETED

    Miami, Florida, 33136, United States

  • The Chaim Sheba Medical Center /ID# 254884

    COMPLETED

    Ramat Gan, Tel Aviv, 5265601, Israel

  • University Health Network_Princess Margaret Cancer Centre /ID# 243936

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • University of Arizona Cancer Center - Tucson /ID# 247752

    RECRUITING

    Tucson, Arizona, 85724, United States

  • University of Nebraska Medical Center /ID# 246715

    RECRUITING

    Omaha, Nebraska, 68198, United States

  • University of Texas Health San Antonio MD Anderson Cancer Center /ID# 256234

    RECRUITING

    San Antonio, Texas, 78229, United States

Conditions

Explore the condition pages connected to this study.

CHRONIC LYMPHOCYTIC LEUKEMIA DIFFUSE LARGE B CELL LYMPHOMA FOLLICULAR LYMPHOMA